Overview of Therapeutic Drug Monitoring of Biologic Agents in Patients With Inflammatory Bowel Disease

Yazar: Cheifetz, Adam
Yayımlandı Gastroenterol Hepatol (N Y) (2017)

Management of Active Crohn Disease

Yazar: Cheifetz, Adam S.
Yayımlandı JAMA (2013)

Higher Adalimumab Drug Levels Are Associated with Mucosal Healing in Patients with Crohn’s Disease

Yazar: Papamichael, Konstantinos, Cheifetz, Adam S.
Yayımlandı J Crohns Colitis (2016)

Use of anti-TNF drug levels to optimise patient management

Yazar: Papamichael, Konstantinos, Cheifetz, Adam S
Yayımlandı Frontline Gastroenterol (2016)

Defining and predicting deep remission in patients with perianal fistulizing Crohn’s disease on anti-tumor necrosis factor therapy

Yazar: Papamichael, Konstantinos, Cheifetz, Adam S
Yayımlandı World J Gastroenterol (2017)

Letter: infliximab concentrations during induction therapy - one size doesn’t fit all.

Yazar: Papamichael, Konstantinos, Cheifetz, Adam S.
Yayımlandı Aliment Pharmacol Ther (2018)

Therapeutic drug monitoring in IBD: for every patient and every drug?

Yazar: Papamichael, Konstantinos, Cheifetz, Adam S.
Yayımlandı Curr Opin Gastroenterol (2019)

Proactive Adalimumab Monitoring in Inflammatory Bowel Disease: Current Data and Future Perspectives

Yazar: Papamichael, Konstantinos, Cheifetz, Adam S
Yayımlandı J Crohns Colitis (2020)

Therapeutic drug monitoring in patients on biologics – lessons from gastroenterology

Yazar: Papamichael, Konstantinos, Cheifetz, Adam S.
Yayımlandı Curr Opin Rheumatol (2020)

The Use of Complementary and Alternative Medicine in Patients With Inflammatory Bowel Disease

Yazar: Lin, Steven C., Cheifetz, Adam S.
Yayımlandı Gastroenterol Hepatol (N Y) (2018)

The cost and benefit of anti-TNF therapy from a population perspective—for what it’s worth

Yazar: Frasca, Joseph D., Cheifetz, Adam S.
Yayımlandı Ann Transl Med (2019)

Varicella Zoster Virus Infection in Patients with Inflammatory Bowel Disease

Yazar: Ham, Maggie, Cullen, Garret, Cheifetz, Adam S.
Baskı/Yayın Bilgisi 2013

Etiology and Management of Lack or Loss of Response to Anti–Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease

Yazar: Fine, Sean, Papamichael, Kostantinos, Cheifetz, Adam S.
Yayımlandı Gastroenterol Hepatol (N Y) (2019)

Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis

Yazar: Nanda, Kavinderjit S., Cheifetz, Adam S., Moss, Alan C.
Baskı/Yayın Bilgisi 2012

The Role of Mucosal Healing in the Treatment of Patients with Inflammatory Bowel Disease

Yazar: Vaughn, Byron P., Shah, Sveta, Cheifetz, Adam S.
Baskı/Yayın Bilgisi 2014

Biologic Concentration Testing in Inflammatory Bowel Disease

Yazar: Vaughn, Byron P., Sandborn, William J., Cheifetz, Adam S.
Yayımlandı Inflamm Bowel Dis (2015)

Outcomes after Infliximab Therapy Escalation in Ambulatory Patients with Moderately Active Ulcerative Colitis: Infliximab in Ulcerative Colitis

Yazar: Rostholder, Emily, Ahmed, Awais, Cheifetz, Adam S, Moss, Alan C
Baskı/Yayın Bilgisi 2012

Varicella Zoster Meningoradiculitis in Crohn’s Disease Treated with 6-Mercaptopurine

Yazar: Cullen, Garret, Krakower, Douglas, Mitty, Jennifer A., Cheifetz, Adam S.
Yayımlandı Inflamm Bowel Dis (2011)

Long-term outcome of infliximab optimization for overcoming immunogenicity in patients with inflammatory bowel disease

Yazar: Papamichael, Konstantinos, Vajravelu, Ravy K., Osterman, Mark T., Cheifetz, Adam S.
Yayımlandı Dig Dis Sci (2018)

Maintenance adalimumab concentrations are associated with biochemical, endoscopic and histologic remission in inflammatory bowel disease

Yazar: Juncadella, Anna, Papamichael, Konstantinos, Vaughn, Byron P., Cheifetz, Adam S.
Yayımlandı Dig Dis Sci (2018)